Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

Sonia Christian, MD, Kelley E. Kozma, DO, Stephanie Barath, Ardaman Shergill, MD, Damiano Rondelli, MD, David Peace, MD, Santosh L. Saraf, MD, Annie Lee Oh, MD, Karen Sweiss, PharmD, Irum Khan, MBBS, Pritesh Patel, MD, Arkadiusz Dudek, MD PhD, John G. Quigley

Blood (2018) 132 (Supplement 1): 5218.

https://doi.org/10.1182/blood-2018-99-111412

Published: 2018

Journal Articles

Increased Incidence of Symptomatic Hyponatremia with Voriconazole Prophylaxis during Cyclophosphamide Based Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplantation

Anant Gokarn, MD, Vikram Gota, MDPGDCT, Gautam Goyal, MDDM, Alok Gupta, MD, Sachin Punatar, MD DM, Pravin Patil, MSc, Krunal Kavathiya, MPharm, Kamal Pathak, Murari Gujjar, Libin Mathew, Bhausaheb Bagal, MD DM., Sadhana Kannan, MSc, Navin Khattry, MDDM

Blood (2014) 124 (21): 2467.

https://doi.org/10.1182/blood.V124.21.2467.2467

Published: 2014

Journal Articles

Hospitalization or Outpatient Treatment for Acute Pulmonary Embolism - a Retrospective Cohort Study of 439 Consecutive Patients with Community-Aquired Pulmonary Embolism

Sebastian Werth, MD, Virginia Kamvissi, Eberhard Kuhlisch, Jan Beyer-Westendorf, MD

Blood (2012) 120 (21): 3416.

https://doi.org/10.1182/blood.V120.21.3416.3416

Published: 2012

Journal Articles

Rituximab, Cyclophosphamide, Bortezomib and Prednisone (R-CBorP): Final Results of a Phase I Trial Evaluating Two Dosing Schedules and the Safety of Overlapping Pegfilgrastim in Patients with Relapsed/Refractory Indolent and Mantle Cell Lymphomas.

John Gerecitano, MD, PhD, Carol S. Portlock, MD, Paul A. Hamlin, Jr., MD, Craig H Moskowitz, MD, Ariela Noy, MD, David J. Straus, MD, Philip Schulman, MD, Otilia Dumitrescu, MD, Debra Sarasohn, MD, Jennifer Pappanicholaou, RN, Alexia Iassonos, Zhigang Zhang, Endri Horanlli, Celeste N Rojas, Andrew D. Zelenetz, MD, PhD, Owen A O'Connor, Md, PhD

Blood (2009) 114 (22): 3708.

https://doi.org/10.1182/blood.V114.22.3708.3708

Published: 2009

Journal Articles

Epistatic Interaction between Fibrinogen alpha and gamma Genes and Factor V Leiden in Children with Venous Thrombosis: Results from a Family-Based Association Study.

Ulrike Nowak-Gottl, MD, Hartmut Weiler, PhD, Tanja Seehafer, Sabine Thedieck, Monika Stoll, PhD

Blood (2007) 110 (11): 1640.

https://doi.org/10.1182/blood.V110.11.1640.1640

Published: 2007

Journal Articles

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

John Gerecitano, MD, PhD, Carol Portlock, MD, Ariela Noy, MD, Paul Hamlin, MD, Craig Moskowitz, MD, David Straus, MD, Steven M. Horwitz, MD, Maria Lia Palomba, MD, Otilia-Liana Dumitrescu, MD, Jennifer Pappanicholaou, Ellen Neylon, Rachel Hamelers, Andrew Zelenetz, MD,PhD, Thomas J. Myers, MD, Anthony L. Boral, MD, Owen A. O’Connor, MD,PhD

Blood (2006) 108 (11): 2759.

https://doi.org/10.1182/blood.V108.11.2759.2759

Published: 2006

NARROW

A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

Increased Incidence of Symptomatic Hyponatremia with Voriconazole Prophylaxis during Cyclophosphamide Based Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplantation

Hospitalization or Outpatient Treatment for Acute Pulmonary Embolism - a Retrospective Cohort Study of 439 Consecutive Patients with Community-Aquired Pulmonary Embolism

Rituximab, Cyclophosphamide, Bortezomib and Prednisone (R-CBorP): Final Results of a Phase I Trial Evaluating Two Dosing Schedules and the Safety of Overlapping Pegfilgrastim in Patients with Relapsed/Refractory Indolent and Mantle Cell Lymphomas.

Epistatic Interaction between Fibrinogen alpha and gamma Genes and Factor V Leiden in Children with Venous Thrombosis: Results from a Family-Based Association Study.

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

Email alerts

ASH Publications

American Society of Hematology

A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

Increased Incidence of Symptomatic Hyponatremia with Voriconazole Prophylaxis during Cyclophosphamide Based Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplantation

Hospitalization or Outpatient Treatment for Acute Pulmonary Embolism - a Retrospective Cohort Study of 439 Consecutive Patients with Community-Aquired Pulmonary Embolism

Rituximab, Cyclophosphamide, Bortezomib and Prednisone (R-CBorP): Final Results of a Phase I Trial Evaluating Two Dosing Schedules and the Safety of Overlapping Pegfilgrastim in Patients with Relapsed/Refractory Indolent and Mantle Cell Lymphomas.

Epistatic Interaction between Fibrinogen alpha and gamma Genes and Factor V Leiden in Children with Venous Thrombosis: Results from a Family-Based Association Study.

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only